A Study Investigating Plasma Abacavir and Its Intracellular Anabolite Carbovir-Triphosphate Pharmacokinetics in the Absence and in the Presence of Darunavir/Ritonavir or Raltegravir in HIV-Infected Subjects.

Trial Profile

A Study Investigating Plasma Abacavir and Its Intracellular Anabolite Carbovir-Triphosphate Pharmacokinetics in the Absence and in the Presence of Darunavir/Ritonavir or Raltegravir in HIV-Infected Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2012

At a glance

  • Drugs Abacavir; Darunavir; Nucleoside reverse transcriptase inhibitors; Raltegravir; Ritonavir
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Jan 2012 Results published in Antiviral Therapy.
    • 20 Nov 2009 Actual patient number (29) added as reported by ClinicalTrials.gov.
    • 20 Nov 2009 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top